Compression Occlusion vs Vascular Occlusion — and Why You Can Have Both

Injectors are taught one mechanism of ischemia: product enters a vessel, travels, lodges, and the territory downstream loses its blood supply. That is the intravascular event, and it deserves the attention it gets. But it is not the only way filler stops perfusion, and treating it as the only way produces a specific blind spot — the patient whose perfusion is failing because of where the product sits, not because of what is inside the vessel.

Compression occlusion is loss of flow caused by extravascular product and the tissue response to it pressing on a vessel from the outside. It has a different mechanism, a different time course and a different relationship to technique. And critically, the two are not alternatives. You can have both at once, in the same territory, in the same patient.

Two mechanisms, described properly

Intravascular occlusion. The needle or cannula tip enters the lumen and product is delivered inside the vessel. The material behaves as an embolus, travelling with or against flow depending on injection pressure and vessel caliber, and lodging where the vessel narrows. The onset is typically immediate and the territory affected is defined by the vascular anatomy downstream of the lodgement point. This is the mechanism that produces the classic sudden blanching or dusky mottling on the table.

Compression occlusion. Product sits outside the vessel, in the tissue, and exerts pressure on the vessel wall. Vessels are compliant, low-pressure structures compared with the tissue pressures a bolus can generate, and veins collapse at far lower pressures than arteries — venous outflow obstruction alone will produce congestion, duskiness and swelling that then worsens the local pressure problem. Onset may be immediate if the bolus is large enough, or it may be delayed over hours as inflammatory edema and the hygroscopic behavior of hyaluronic acid expand the volume occupying that space.

The second mechanism is the one that explains a category of presentation injectors find confusing: unusual swelling with pain out of proportion, appearing some hours after an uneventful treatment, in a patient whose immediate post-procedure assessment was entirely normal. Nothing was injected into a vessel. The tissue simply cannot accommodate what was placed in it.

Why anatomy decides whether volume becomes pressure

The same volume of product is benign in one location and dangerous in another, and the variable is compliance.

Tissue that can expand tolerates volume. Tissue that cannot converts volume directly into pressure. The regions where injectors get into trouble are the ones with limited room: the nose, where skin is tight, compartments are small and the vascular supply is end-arterial in character; the glabella, where the tissue is tethered and the supratrochlear territory has limited collateral rescue; the tear trough and infraorbital region, where a small bolus in a confined plane has an outsized effect; and periosteal planes generally, where product is placed against an unyielding surface.

The lips are a special case in the other direction — they swell impressively and accommodate a great deal, which is why expected perioral edema is so pronounced, and also why a genuinely compressive lip problem hides inside a normal-looking amount of swelling. Knowing the expected picture in that region, as covered in our discussion of common lip filler reactions, is what lets you tell the difference.

This is not a reason to avoid those regions. It is a reason to understand that decisions about how much product goes in one place are perfusion decisions, not only aesthetic ones. Treatment planning across facial volume loss has to account for what the compartment can physically hold.

Volume per pass is the control variable

This is where compression stops being a theoretical mechanism and becomes a technique rule.

I do not exceed 0.1 to 0.15 mL on any single pass. That figure is doing two separate jobs. It limits the embolic load if a vessel is unknowingly entered — less product inside a vessel means a smaller embolus and a smaller territory at risk. And it limits the compressive load if the product is correctly placed extravascularly — less product in one spot means less pressure on the structures next to it.

Same number, two mechanisms. That is why the rule holds regardless of whether you are using a needle or a cannula, and regardless of how confident you are about your plane.

These figures reflect Michelle Langston's clinical practice as taught in Empire Medical Training's hands-on curriculum. Technique is learned under supervision; this article is educational and is not a substitute for training.

The corollary is a technique discipline rather than a number: volume is delivered in small increments across multiple passes and multiple planes rather than as a single depot. Total volume in a region can be identical between two injectors, with entirely different compressive consequences, depending on how it was distributed. This is one of the clearest examples of a foundational habit that becomes a safety behavior, and it is the sort of thing that is learned by having someone watch your hands — which is the argument for supervised, anatomically grounded training rather than technique picked up piecemeal.

Why you can have both — and usually should assume you might

Consider what actually happens during a problematic pass. The tip is somewhere near a vessel. Some product is delivered into the lumen. The remainder of the bolus is delivered into the perivascular tissue immediately around it. That is one pass producing both an intraluminal embolus and a perivascular mass, at the same site, affecting the same vessel.

Then the tissue responds. Inflammation follows the injury. Edema accumulates. The hyaluronic acid draws water. Vessel spasm may occur in response to mechanical irritation. Every one of those adds pressure in a space that is already compromised, and reduced perfusion itself drives further inflammation and swelling — a loop that tightens over hours.

The practical consequence is that the mechanisms are not cleanly separable at the bedside and you should not try to separate them in the moment. A clinician who decides "this is only compression" and plans to observe has made a diagnosis that the findings cannot support and that would not change the immediate management anyway.

What the distinction does and does not change

It does not change the immediate response. Stop injecting. Assess perfusion. If perfusion is compromised, flood the territory with hyaluronidase, oriented to where the needle tip was rather than to the entry point. Hyaluronidase addresses both mechanisms — it degrades intraluminal hyaluronic acid after crossing the vessel wall, and it degrades the extravascular bolus that is doing the compressing. You do not need to know which mechanism dominates in order to do the right thing. Our piece on dissolving filler covers the enzyme in detail.

It does change how you read the time course. A compression-dominant picture can arrive late, as swelling builds, in a patient who looked fine on leaving. That is an argument for the same-day contact and the low threshold for bringing someone back in, rather than an argument for a different treatment.

It does change your interpretation of a partial response. If perfusion improves after hyaluronidase and then deteriorates again as edema re-accumulates, that behavior is consistent with a compressive component and is a reason to keep the patient under close observation and to be willing to re-treat, not a reason to conclude the problem is resolved.

It does change the conversation about the product involved. Hyaluronidase degrades hyaluronic acid. It does not degrade calcium hydroxylapatite, poly-L-lactic acid, polymethylmethacrylate or autologous fat. Compression from a non-hyaluronic-acid product is a materially different clinical problem with fewer reversal options, which is a reason for particular volume discipline and particular anatomical caution when using those materials in confined compartments.

It does change your prevention strategy. Aspiration, small increments, slow injection, appropriate instrument choice and knowledge of the vascular course are aimed at the intravascular mechanism. Volume per pass, distribution across planes, product selection for the compartment and awareness of post-injection swelling are aimed at the compressive one. A prevention strategy that only addresses the first leaves half the mechanism unmanaged.

The assessment implication

None of this changes the recognition sequence, which is the point worth ending on. You still scan the territory rather than the injection point. You still ask about pain trajectory. You still compare capillary refill and temperature against the matched contralateral side. You still follow the vascular trajectory rather than the puncture.

What the compression mechanism adds is a reason to extend that sequence in time. Intravascular events tend to declare themselves while you are still in the room. Compressive events may not — they can build with the swelling, hours after the patient has gone home, which makes the evening contact and the willingness to bring someone back in the actual detection system for that half of the problem.

If you are building both halves of that prevention strategy into your practice, Empire's Complete Dermal Filler Training teaches placement, volume discipline and assessment under hands-on supervision, which is where habits of distribution and depth are actually formed.

Related guides in this cluster

Part of Vascular Occlusion: Recognition and Response.

Clinical GuideThe Expected Filler Injection Response — Building the Baseline That Lets You Recognize IschemiaThe expected filler injection response — erythema, edema, ecchymosis — and how a trained normal baseline makes early ischemia recogniza Clinical GuideThe Golden Triangle — Why the Filler Deposit Site Isn't Where You Put the Needle InThe filler deposit site sits at the needle tip, not the entry point — about half an inch away, further with a cannula. Why that gap dec Clinical GuideImmediate, Early and Late — The Three Windows of Vascular Occlusion OnsetVascular occlusion onset is not one moment. Organize the picture into immediate, early and late windows — detection runs days past the